董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jose Carlos Gutierrez Ramos -- Director 55 26.76万美元 未持股 2018-04-27
Craig A. Wheeler Director,President and Chief Executive Officer 57 478.46万美元 未持股 2018-04-27
Steven C. Gilman Director 65 26.76万美元 未持股 2018-04-27
Thomas P. Koestler Director 66 26.76万美元 未持股 2018-04-27
Corey N. Fishman Director 53 26.83万美元 未持股 2018-04-27
Georges Gemayel Director 58 26.96万美元 未持股 2018-04-27
Bruce L. Downey Director 70 27.26万美元 未持股 2018-04-27
Elizabeth Stoner Director 67 26.96万美元 未持股 2018-04-27
James R. Sulat Director and Chairman 67 29.83万美元 未持股 2018-04-27

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Scott M. Storer Senior Vice President and Chief Financial Officer 43 56.86万美元 未持股 2018-04-27
Santiago Arroyo Senior Vice President, Development and Chief Medical Officer 58 232.10万美元 未持股 2018-04-27
Young Kwon Senior Vice President, Corporate Development and Strategy 46 未披露 未持股 2018-04-27
Craig A. Wheeler Director,President and Chief Executive Officer 57 478.46万美元 未持股 2018-04-27
Ganesh Venkataraman Kaundinya Chief Operating Officer and Chief Scientific Officer 51 151.69万美元 未持股 2018-04-27
Bruce A. Leicher Senior Vice President, General Counsel and Secretary 62 151.27万美元 未持股 2018-04-27

董事简历

中英对照 |  中文 |  英文
Jose Carlos Gutierrez Ramos

Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来,一直担任高级副总裁兼首席科学官。在加入Danaher 之前,Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie,Inc.的药物发现副总裁;于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官;于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。


Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020.
Jose Carlos Gutierrez Ramos自2020年12月加入Danaher 以来,一直担任高级副总裁兼首席科学官。在加入Danaher 之前,Gutierrez-Ramos博士于2020年1月至2020年12月担任生物制药公司AbbVie,Inc.的药物发现副总裁;于2018年8月至2020年1月担任生物技术公司Repertoire Immune Medicines的总裁兼首席执行官;于2015年8月至2018年8月担任生物制药公司Synlogic, Inc.的总裁兼首席执行官。
Jose Carlos Gutierrez Ramos,has served as Senior Vice President – Chief Science Officer since joining Danaher in December 2020. Prior to joining Danaher, Dr. Gutierrez-Ramos served as Vice President – Drug Discovery for AbbVie, Inc., a biopharmaceutical company, from January 2020 to December 2020; and as President and CEO of Repertoire Immune Medicines, a biotechnology company, from August 2018 until January 2020.
Craig A. Wheeler

Craig A. Wheeler,从2007年5月开始担任董事长,目前担任审计委员会成员和公司管理委员会和行政委员会主席。他在Momenta制药公司董事兼CEO。2006年8月加入Momenta 之前,他在Chiron生物制药公司(Chiron公司的一个分公司)担任了5年总裁,直到2006年被诺华制药公司收购。他负责公司各方面事务包括商业广告、研究、发展和制造。他现在在Generic制药公司董事会任职,也是其行政委员会成员。他目前也在康乃尔生物医学工程咨询委员会和波士顿儿童医院Gene Partnership咨询委员会任职。他拥有康乃尔大学化学工程理科学士和硕士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位,专业为市场营销和金融。


Craig A. Wheeler has served as our president and a director since August 2006 and was appointed our chief executive officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as president of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler serves on the board of Amicus Therapeutics, Inc., including serving on the science and compensation committees. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co., Ltd., from September 2005 to January 2015 including serving on the corporate governance and audit committees, and serving as chairman of the board beginning May 2007. Mr. Wheeler has been a member of the board of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, for over eight years, including serving as chairman of the board from 2014 to 2016 and as a member of the executive committee for the past six years. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Craig A. Wheeler,从2007年5月开始担任董事长,目前担任审计委员会成员和公司管理委员会和行政委员会主席。他在Momenta制药公司董事兼CEO。2006年8月加入Momenta 之前,他在Chiron生物制药公司(Chiron公司的一个分公司)担任了5年总裁,直到2006年被诺华制药公司收购。他负责公司各方面事务包括商业广告、研究、发展和制造。他现在在Generic制药公司董事会任职,也是其行政委员会成员。他目前也在康乃尔生物医学工程咨询委员会和波士顿儿童医院Gene Partnership咨询委员会任职。他拥有康乃尔大学化学工程理科学士和硕士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位,专业为市场营销和金融。
Craig A. Wheeler has served as our president and a director since August 2006 and was appointed our chief executive officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as president of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler serves on the board of Amicus Therapeutics, Inc., including serving on the science and compensation committees. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co., Ltd., from September 2005 to January 2015 including serving on the corporate governance and audit committees, and serving as chairman of the board beginning May 2007. Mr. Wheeler has been a member of the board of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, for over eight years, including serving as chairman of the board from 2014 to 2016 and as a member of the executive committee for the past six years. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Steven C. Gilman

Steven C. Gilman,2010年9月开始,他就是研究开发部的执行副总裁和首席战略官。在这之前,2008年2月到2010年9月,他是发现和临床发展部的高级副总裁和首席战略官。2007年4月到2008年2月,他是ActivBiotics公司,(一家私营生物制药公司)的董事会主席和首席执行官。2004年3月到2007年4月,他是ActivBiotics公司的董事会成员、总裁和首席执行官。他任职于马萨诸塞州生物技术委员会和inhibikase疗法公司,(一家强调提高临床研究质量和改善患者安全的非营利组织)。另外,他任职于科学领导和美国药物研究和制造商协会 ,任职于东北大学医药资讯委员会和宾夕法尼亚州州立大学生物技术咨询委员会。


Steven C. Gilman,joined Scynexis, Inc. Board on February 25, 2015. Prior to his retirement in April 2019, Dr. Gilman served as the Chairman of the board of directors and President and Chief Executive Officer of ContraFect Corporation (Nasdaq: CFRX), a publicly-traded biotechnology company, since May 2015. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, a publicly-traded biopharmaceutical company, until its acquisition by Merck & Co in January 2015. Prior to joining Cubist, Dr. Gilman served as chairman of the board of directors and CEO of ActivBiotics from March 2004 to October 2007. Prior to ActivBiotics, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., from October 2000 to March 2004 where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently serves on the board of directors of Vericel Corporation (Nasdaq: VCEL), Akebia Therapeutics, Inc. (Nasdaq: AKBA), and ContraFect Corporation (Nasdaq: CFRX), and previously served on the board of directors of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA). Dr. Gilman received his Ph.D. and MS degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinical and Research Foundation and received a B.A. in microbiology from Miami University of Ohio.
Steven C. Gilman,2010年9月开始,他就是研究开发部的执行副总裁和首席战略官。在这之前,2008年2月到2010年9月,他是发现和临床发展部的高级副总裁和首席战略官。2007年4月到2008年2月,他是ActivBiotics公司,(一家私营生物制药公司)的董事会主席和首席执行官。2004年3月到2007年4月,他是ActivBiotics公司的董事会成员、总裁和首席执行官。他任职于马萨诸塞州生物技术委员会和inhibikase疗法公司,(一家强调提高临床研究质量和改善患者安全的非营利组织)。另外,他任职于科学领导和美国药物研究和制造商协会 ,任职于东北大学医药资讯委员会和宾夕法尼亚州州立大学生物技术咨询委员会。
Steven C. Gilman,joined Scynexis, Inc. Board on February 25, 2015. Prior to his retirement in April 2019, Dr. Gilman served as the Chairman of the board of directors and President and Chief Executive Officer of ContraFect Corporation (Nasdaq: CFRX), a publicly-traded biotechnology company, since May 2015. He previously served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, a publicly-traded biopharmaceutical company, until its acquisition by Merck & Co in January 2015. Prior to joining Cubist, Dr. Gilman served as chairman of the board of directors and CEO of ActivBiotics from March 2004 to October 2007. Prior to ActivBiotics, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., from October 2000 to March 2004 where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently serves on the board of directors of Vericel Corporation (Nasdaq: VCEL), Akebia Therapeutics, Inc. (Nasdaq: AKBA), and ContraFect Corporation (Nasdaq: CFRX), and previously served on the board of directors of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA). Dr. Gilman received his Ph.D. and MS degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinical and Research Foundation and received a B.A. in microbiology from Miami University of Ohio.
Thomas P. Koestler

Thomas P. Koestler,2011年1月开始他是董事。2010年3月开始他是Vatera医疗合伙公司(一家私营企业)的执行者。在加入Vatera医疗合伙公司前,2003年加入时,他是先灵葆雅公司(Schering-Plough Corporation 一家制药公司)的执行副总裁,是先灵葆雅公司(Schering-Plough Corporation)调查协会的总裁,是药物的研究与开发的总裁。他也在制药公司,诺华公司(Novartis AG), Ortho-McNeil 公司和Bristol-Myers Squibb公司担任高级职位。他也是诺和诺德公司(Novo Nordisk A/S)和一些私营公司的董事会成员。他拥有德门学院(Daemen College)生物学和遗传学学士学位,纽约州立大学(the State University of New York)博士学位,在那儿他主修医学和病理学。


Thomas P. Koestler, Ph.D., has been a director since January 2011. Since March 2010 Dr. Koestler has served as executive-in-residence at Vatera Healthcare Partners, a private equity company. Prior to joining Vatera Healthcare Partners, Dr. Koestler was executive vice president of Schering-Plough Corporation, a pharmaceutical company, and president of Schering-Plough Research Institute, the pharmaceutical research and development arm of Schering-Plough Corporation, which he joined in 2003. Dr. Koestler has also held senior positions at Pharmacia Corporation, Novartis AG, Ortho-McNeil and Bristol-Myers Squibb. Dr. Koestler is also a member of the board of directors of Melinta Therapeutics, a publicly traded biopharmaceutical company, including serving on the nominating and corporate governance and compensation committees, and of a privately-held company. Dr. Koestler holds a B.S. degree in biology and genetics from Daemen College and a Ph.D. from the State University of New York, where he studied medicine and pathology.
Thomas P. Koestler,2011年1月开始他是董事。2010年3月开始他是Vatera医疗合伙公司(一家私营企业)的执行者。在加入Vatera医疗合伙公司前,2003年加入时,他是先灵葆雅公司(Schering-Plough Corporation 一家制药公司)的执行副总裁,是先灵葆雅公司(Schering-Plough Corporation)调查协会的总裁,是药物的研究与开发的总裁。他也在制药公司,诺华公司(Novartis AG), Ortho-McNeil 公司和Bristol-Myers Squibb公司担任高级职位。他也是诺和诺德公司(Novo Nordisk A/S)和一些私营公司的董事会成员。他拥有德门学院(Daemen College)生物学和遗传学学士学位,纽约州立大学(the State University of New York)博士学位,在那儿他主修医学和病理学。
Thomas P. Koestler, Ph.D., has been a director since January 2011. Since March 2010 Dr. Koestler has served as executive-in-residence at Vatera Healthcare Partners, a private equity company. Prior to joining Vatera Healthcare Partners, Dr. Koestler was executive vice president of Schering-Plough Corporation, a pharmaceutical company, and president of Schering-Plough Research Institute, the pharmaceutical research and development arm of Schering-Plough Corporation, which he joined in 2003. Dr. Koestler has also held senior positions at Pharmacia Corporation, Novartis AG, Ortho-McNeil and Bristol-Myers Squibb. Dr. Koestler is also a member of the board of directors of Melinta Therapeutics, a publicly traded biopharmaceutical company, including serving on the nominating and corporate governance and compensation committees, and of a privately-held company. Dr. Koestler holds a B.S. degree in biology and genetics from Daemen College and a Ph.D. from the State University of New York, where he studied medicine and pathology.
Corey N. Fishman

Corey N. Fishman,从2010年8月到2015年2月,Fishman先生担任Durata Therapeutics, Inc.(一家制药公司,被Actavis plc收购)的首席运营官;从2012年6月到2015年2月,他还担任Durata Therapeutics, Inc.的首席财务官。从2008年到2010年,Fishman先生担任制药公司GANIC Pharmaceuticals, Inc.的首席财务官。从2002年到2008年,Fishman先生在MedPointe Healthcare, Inc.(一家被Meda AB收购的专业制药公司)担任各种职务,包括从2006年到2008年担任首席财务官。Fishman先生此前曾担任Momenta Pharmaceuticals, Inc.(生物技术公司)的董事会成员(从2016年9月到2020年6月)和biospecific Technology Corporation(生物制药公司)的董事会成员(从2020年4月到2020年12月被Endo International plc收购)。他持有Illinoi大学厄巴纳-香槟分校的经济学学士学位和Purdue大学Krannert School of Management的金融学硕士学位。


Corey N. Fishman,from August 2010 to February 2015, Mr. Fishman served as chief operating officer of Durata Therapeutics, Inc., a pharmaceutical company acquired by Actavis plc, a pharmaceutical company, and he also served as chief financial officer of Durata Therapeutics, Inc., from June 2012 to February 2015. From 2008 to 2010, Mr. Fishman served as chief financial officer of GANIC Pharmaceuticals, Inc., a pharmaceutical company. From 2002 to 2008, Mr. Fishman served in a variety of roles at MedPointe Healthcare, Inc., a specialty pharmaceutical company acquired by Meda AB, including as chief financial officer from 2006 to 2008. Mr. Fishman previously served on the board of directors of Momenta Pharmaceuticals, Inc., a biotechnology company, from September 2016 until June 2020 and BioSpecifics Technology Corporation, a biopharmaceutical company, from April 2020 until its acquisition by Endo International plc in December 2020. Mr. Fishman holds a B.A. in economics from the University of Illinois at Urbana-Champaign and an M.S.M. in finance from the Krannert School of Management at Purdue University.
Corey N. Fishman,从2010年8月到2015年2月,Fishman先生担任Durata Therapeutics, Inc.(一家制药公司,被Actavis plc收购)的首席运营官;从2012年6月到2015年2月,他还担任Durata Therapeutics, Inc.的首席财务官。从2008年到2010年,Fishman先生担任制药公司GANIC Pharmaceuticals, Inc.的首席财务官。从2002年到2008年,Fishman先生在MedPointe Healthcare, Inc.(一家被Meda AB收购的专业制药公司)担任各种职务,包括从2006年到2008年担任首席财务官。Fishman先生此前曾担任Momenta Pharmaceuticals, Inc.(生物技术公司)的董事会成员(从2016年9月到2020年6月)和biospecific Technology Corporation(生物制药公司)的董事会成员(从2020年4月到2020年12月被Endo International plc收购)。他持有Illinoi大学厄巴纳-香槟分校的经济学学士学位和Purdue大学Krannert School of Management的金融学硕士学位。
Corey N. Fishman,from August 2010 to February 2015, Mr. Fishman served as chief operating officer of Durata Therapeutics, Inc., a pharmaceutical company acquired by Actavis plc, a pharmaceutical company, and he also served as chief financial officer of Durata Therapeutics, Inc., from June 2012 to February 2015. From 2008 to 2010, Mr. Fishman served as chief financial officer of GANIC Pharmaceuticals, Inc., a pharmaceutical company. From 2002 to 2008, Mr. Fishman served in a variety of roles at MedPointe Healthcare, Inc., a specialty pharmaceutical company acquired by Meda AB, including as chief financial officer from 2006 to 2008. Mr. Fishman previously served on the board of directors of Momenta Pharmaceuticals, Inc., a biotechnology company, from September 2016 until June 2020 and BioSpecifics Technology Corporation, a biopharmaceutical company, from April 2020 until its acquisition by Endo International plc in December 2020. Mr. Fishman holds a B.A. in economics from the University of Illinois at Urbana-Champaign and an M.S.M. in finance from the Krannert School of Management at Purdue University.
Georges Gemayel

自2012年2月以来,Georges Gemayel曾担任董。2007年4月至2011年12月,他曾任 Adolor Corporation董事,这是一家被 Cubist Pharmaceuticals收购的上市临床开发公司。从2010年4月至2010年10月,他担任FoldRx Pharmaceuticals执行主席,这是一家被Pfizer Inc 收购的私人持有的药物发现和临床开发公司。从2008年6月至2009年11月,他担任Altus Pharmaceuticals Inc主席,首席执行官兼董事,这是一家公开上市的制药公司。从2003年到2008年5月,他曾担任Genzyme Corporation的Therapeutics and Biosurgery 执行副总裁,在那里他负责Genzyme的全球治疗,移植,肾脏和生物外科业务。从2000年到2003年,他被聘为Hoffmann-La Roche 国家级专科护理副总裁,负责其在美国的皮肤科,肿瘤科,移植,肝炎和艾滋病病毒业务。他1988年加入 Hoffmann-La Roche ,在他的任期期间一直任要职。他获得St. Joseph University 药剂学博士学位,学校位于黎巴嫩贝鲁特和Paris-Sud University。药剂学博士学位。2009年11月,他任总裁,首席执行官兼董事时,Altus Pharmaceuticals 根据美国破产法第7章提出自愿申请救济,并在此时停止了运营。从2011年2月至2012年12月,他担任Syndexa Pharmaceuticals Corp执行主席,这是一家私人控股公司。他还担任Vascular Magnetics, Inc., Epitherapeutics, and Oxthera 董事局主席,是Orphazyme ApS以及所有私人持有的生物制药企业中的一员。他也是 Prosensa,一家上市医药公司,以及 International Institute of New England, 一个非营利性组织的董事。


Georges Gemayel has served as a member of board of directors since November 2012 and as Chairman of board of directors since September 2014. Mr. Gemayel is currently chairman of the board of directors of Dynacure SAS, Enterome SA and OxThera AB and Supernus Pharmaceuticals Inc. Mr. Gemayel has been a partner in Gemayel Investment LLC since 2012 as well as a director of the non-governmental organization, St. Andrew's School in Ngong Inc. and a trustee of the Gemayel Family Foundation. In the past five years, Mr. Gemayel was a member of the board of directors of Momenta Pharmaceuticals Inc, chairman of the board of directors of Dimension Therapeutics Inc., Epitherapeutics ApS and Vascular Magnetics Inc., a member of the board of directors of NPS Pharmaceuticals Inc. and Raptor Pharmaceuticals Corp., a consultant for Novo Ventures 1 A/S, Fidelity Ventures and Noveome Biotherapeutics Inc. as well as a director of the nongovernmental organization, International Institute of New England. Mr. Gemayel holds a Master's degree and a PhD degree in Pharmacology from Paris-Sud University and a Docteur d' Exercice en Pharmacie from the St. Joseph University.
自2012年2月以来,Georges Gemayel曾担任董。2007年4月至2011年12月,他曾任 Adolor Corporation董事,这是一家被 Cubist Pharmaceuticals收购的上市临床开发公司。从2010年4月至2010年10月,他担任FoldRx Pharmaceuticals执行主席,这是一家被Pfizer Inc 收购的私人持有的药物发现和临床开发公司。从2008年6月至2009年11月,他担任Altus Pharmaceuticals Inc主席,首席执行官兼董事,这是一家公开上市的制药公司。从2003年到2008年5月,他曾担任Genzyme Corporation的Therapeutics and Biosurgery 执行副总裁,在那里他负责Genzyme的全球治疗,移植,肾脏和生物外科业务。从2000年到2003年,他被聘为Hoffmann-La Roche 国家级专科护理副总裁,负责其在美国的皮肤科,肿瘤科,移植,肝炎和艾滋病病毒业务。他1988年加入 Hoffmann-La Roche ,在他的任期期间一直任要职。他获得St. Joseph University 药剂学博士学位,学校位于黎巴嫩贝鲁特和Paris-Sud University。药剂学博士学位。2009年11月,他任总裁,首席执行官兼董事时,Altus Pharmaceuticals 根据美国破产法第7章提出自愿申请救济,并在此时停止了运营。从2011年2月至2012年12月,他担任Syndexa Pharmaceuticals Corp执行主席,这是一家私人控股公司。他还担任Vascular Magnetics, Inc., Epitherapeutics, and Oxthera 董事局主席,是Orphazyme ApS以及所有私人持有的生物制药企业中的一员。他也是 Prosensa,一家上市医药公司,以及 International Institute of New England, 一个非营利性组织的董事。
Georges Gemayel has served as a member of board of directors since November 2012 and as Chairman of board of directors since September 2014. Mr. Gemayel is currently chairman of the board of directors of Dynacure SAS, Enterome SA and OxThera AB and Supernus Pharmaceuticals Inc. Mr. Gemayel has been a partner in Gemayel Investment LLC since 2012 as well as a director of the non-governmental organization, St. Andrew's School in Ngong Inc. and a trustee of the Gemayel Family Foundation. In the past five years, Mr. Gemayel was a member of the board of directors of Momenta Pharmaceuticals Inc, chairman of the board of directors of Dimension Therapeutics Inc., Epitherapeutics ApS and Vascular Magnetics Inc., a member of the board of directors of NPS Pharmaceuticals Inc. and Raptor Pharmaceuticals Corp., a consultant for Novo Ventures 1 A/S, Fidelity Ventures and Noveome Biotherapeutics Inc. as well as a director of the nongovernmental organization, International Institute of New England. Mr. Gemayel holds a Master's degree and a PhD degree in Pharmacology from Paris-Sud University and a Docteur d' Exercice en Pharmacie from the St. Joseph University.
Bruce L. Downey

Bruce L. Downey,2009年6月成为董事。2009年4月,他成为NewSpring Capital公司合伙人。以前他是Barr Pharmaceuticals公司(全球专业制药公司,在全球30多个国家经营,于2008年被Teva Pharmaceuticals公司收购)董事长兼首席执行长。1993年他加入Barr Pharmaceuticals公司,1994年被任命为董事会主席兼首席执行官。他还是Cardinal Health公司(私营公司)董事会成员。1969年他以优异的成绩毕业迈阿密大学后又以优等成绩取得俄亥俄州立大学法律学位。


Bruce L. Downey was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc., a global generic pharmaceutical manufacturer, from 1994 until 2008 when Cardinal Health, Inc. was acquired by Teva Pharmaceutical Industries Ltd. Mr. Downey has served on a part-time basis as a Partner of NewSpring Health Capital II, L.P., a venture capital firm, since 2009. Before his career at Barr Pharmaceuticals, Mr. Downey was a practicing attorney for 20 years, having worked in both private practice and with the U.S. Department of Justice.
Bruce L. Downey,2009年6月成为董事。2009年4月,他成为NewSpring Capital公司合伙人。以前他是Barr Pharmaceuticals公司(全球专业制药公司,在全球30多个国家经营,于2008年被Teva Pharmaceuticals公司收购)董事长兼首席执行长。1993年他加入Barr Pharmaceuticals公司,1994年被任命为董事会主席兼首席执行官。他还是Cardinal Health公司(私营公司)董事会成员。1969年他以优异的成绩毕业迈阿密大学后又以优等成绩取得俄亥俄州立大学法律学位。
Bruce L. Downey was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc., a global generic pharmaceutical manufacturer, from 1994 until 2008 when Cardinal Health, Inc. was acquired by Teva Pharmaceutical Industries Ltd. Mr. Downey has served on a part-time basis as a Partner of NewSpring Health Capital II, L.P., a venture capital firm, since 2009. Before his career at Barr Pharmaceuticals, Mr. Downey was a practicing attorney for 20 years, having worked in both private practice and with the U.S. Department of Justice.
Elizabeth Stoner

Elizabeth Stoner, 医学博士。2011年5月起,她担任我公司董事会成员;2007年10月起,担任MPM Capital的总经理;2010年起,担任生物技术公司Rhythm Pharmaceuticals的首席发展官。加入MPM Capital前, 她担任多职,包括1985年起,担任Merck Research Laboratories全球临床研发运营的高级副总裁。她目前Momenta Pharmaceuticals Inc.的董事, 2009至2010年,担任Metabasis Therapeutics, Inc.的董事。她在Albert Einstein College of Medicine获得医学博士学位,在纽约州立大学(State University of New York)斯托尼布鲁克分校获得化学学士学位,在堪萨斯州渥太华大学(Ottawa University)获得化学学士学位。


Elizabeth Stoner, M.D., has been a director since October 2007. Since September 2012 Dr. Stoner has been the chief development officer at Vascular Pharmaceuticals, Inc., a biotechnology company. From 2010 to 2014 Dr. Stoner was the chief development officer of Rhythm Pharmaceuticals, and since December 2014 she has been a member of Rhythm's Scientific Advisory Board. Since October 2007 Dr. Stoner has served as a managing director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a distinguished 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was senior vice president of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries, including Merck's Japanese subsidiary. Prior to her position at Merck, she was an assistant professor of Pediatrics at Cornell University Medical College. Dr. Stoner served on the board of Radius Health, Inc. from 2011 to 2015. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine.
Elizabeth Stoner, 医学博士。2011年5月起,她担任我公司董事会成员;2007年10月起,担任MPM Capital的总经理;2010年起,担任生物技术公司Rhythm Pharmaceuticals的首席发展官。加入MPM Capital前, 她担任多职,包括1985年起,担任Merck Research Laboratories全球临床研发运营的高级副总裁。她目前Momenta Pharmaceuticals Inc.的董事, 2009至2010年,担任Metabasis Therapeutics, Inc.的董事。她在Albert Einstein College of Medicine获得医学博士学位,在纽约州立大学(State University of New York)斯托尼布鲁克分校获得化学学士学位,在堪萨斯州渥太华大学(Ottawa University)获得化学学士学位。
Elizabeth Stoner, M.D., has been a director since October 2007. Since September 2012 Dr. Stoner has been the chief development officer at Vascular Pharmaceuticals, Inc., a biotechnology company. From 2010 to 2014 Dr. Stoner was the chief development officer of Rhythm Pharmaceuticals, and since December 2014 she has been a member of Rhythm's Scientific Advisory Board. Since October 2007 Dr. Stoner has served as a managing director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a distinguished 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was senior vice president of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries, including Merck's Japanese subsidiary. Prior to her position at Merck, she was an assistant professor of Pediatrics at Cornell University Medical College. Dr. Stoner served on the board of Radius Health, Inc. from 2011 to 2015. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine.
James R. Sulat

James R. Sulat,于2014年4月14日加入我们董事会。从2009年10月到2013年6月,他担任Maxygen公共生物制药公司的首席执行官和首席财务官,从2003年10月到2013年6月,担任Maxygen的董事会成员。2008年6月以来,他担任Momenta公共生物科技公司的董事会成员和审计委员会成员。2008年12月以来,他还担任Momenta董事会的主席。从2005年5月到2009年1月,他曾Memory公共生物制药公司担任各种不同的职位。从2005年5月到2009年2月,他担任Memory的总裁兼首席执行官首席财务官;2005年5月到2008年2月,他担任Memory的总裁兼首席执行官;从2008年2月到2008年11月,他担任首席财务官。从2005年5月到2009年2月,他担任负责人。2005年1月以来,他担任Intercell AG和其继任者公司Valneva SE的监事会成员,两者都为公共欧洲生物技术公司。目前,他担任Valneva副主席监事会和审计委员的主席。他获得了耶鲁大学管理科学学士学位以及斯坦福大学健康服务管理局的工商管理硕士学位。


James R. Sulat has been a director since June 2008 and has served as chairman of the board since December 2008. From October 2009 to June 2013 Mr. Sulat served as the chief executive officer and chief financial officer of Maxygen, Inc., a publicly traded biopharmaceutical company. Mr. Sulat is on the boards of directors of publicly traded biotechnology companies, Valneva SE, AMAG Pharmaceuticals, Inc. and Arch Therapeutics, Inc. During the last five years, Mr. Sulat served as a director of Maxygen, Inc. and Diadexus, Inc., both publicly traded biotechnology companies. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.
James R. Sulat,于2014年4月14日加入我们董事会。从2009年10月到2013年6月,他担任Maxygen公共生物制药公司的首席执行官和首席财务官,从2003年10月到2013年6月,担任Maxygen的董事会成员。2008年6月以来,他担任Momenta公共生物科技公司的董事会成员和审计委员会成员。2008年12月以来,他还担任Momenta董事会的主席。从2005年5月到2009年1月,他曾Memory公共生物制药公司担任各种不同的职位。从2005年5月到2009年2月,他担任Memory的总裁兼首席执行官首席财务官;2005年5月到2008年2月,他担任Memory的总裁兼首席执行官;从2008年2月到2008年11月,他担任首席财务官。从2005年5月到2009年2月,他担任负责人。2005年1月以来,他担任Intercell AG和其继任者公司Valneva SE的监事会成员,两者都为公共欧洲生物技术公司。目前,他担任Valneva副主席监事会和审计委员的主席。他获得了耶鲁大学管理科学学士学位以及斯坦福大学健康服务管理局的工商管理硕士学位。
James R. Sulat has been a director since June 2008 and has served as chairman of the board since December 2008. From October 2009 to June 2013 Mr. Sulat served as the chief executive officer and chief financial officer of Maxygen, Inc., a publicly traded biopharmaceutical company. Mr. Sulat is on the boards of directors of publicly traded biotechnology companies, Valneva SE, AMAG Pharmaceuticals, Inc. and Arch Therapeutics, Inc. During the last five years, Mr. Sulat served as a director of Maxygen, Inc. and Diadexus, Inc., both publicly traded biotechnology companies. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

高管简历

中英对照 |  中文 |  英文
Scott M. Storer

ScottM.Storer自2016年11月以来一直是我们的高级副总裁和首席财务官。在加入Momenta之前,Storer先生是Baxalta,Inc.(一家制药公司)的财务高级副总裁,该公司于2015年7月从Baxter International分拆出来,他在该公司为Baxalta的全球商业,制造,研究与开发和职能团队提供财务领导,内部控制和业务伙伴关系支持。此外,他曾领导Baxalta公司的企业财务规划和分析团队。在此之前,Storer从2008年到2015年7月担任Baxter Bioscience Finance Vice President,为Bioscience US Commercial Organization、全球制造、研究与开发、业务发展和所有支持职能部门提供财务领导、内部控制和业务伙伴关系支持。Storer从1997年到2008年在Baxter担任多个其他职位,包括从2006年到2008年担任Bioscience Operations Finance Vice President。Storer先生在科罗拉多大学博尔德分校(University of Colorado,Boulder)获得学士学位,在西北大学凯洛格管理学院(Kellogg School of Management)获得工商管理硕士学位。


Scott M. Storer has been our Senior Vice President and Chief Financial Officer since November 2016. Prior to joining Momenta, Mr. Storer was Senior Vice President of Finance at Baxalta, Inc., a pharmaceutical company, following its spin-out from Baxter International in July 2015 where he provided financial leadership, internal controls, and business partnership support for Baxalta's global commercial, manufacturing, research and development, and functional teams. In addition, he led Baxalta's corporate financial planning and analysis team. Before that, from 2008 to July 2015 Mr. Storer served as Vice President of BioScience Finance at Baxter, where he provided financial leadership, internal controls and business partnership support to the BioScience US commercial organization, global manufacturing, research and development, business development and all support functions. From 1997 to 2008 Mr. Storer held various other positions at Baxter, including Vice President of BioScience Operations Finance from 2006 to 2008. Mr. Storer received his B.S. from the University of Colorado, Boulder, and his M.B.A. from Northwestern University's Kellogg School of Management.
ScottM.Storer自2016年11月以来一直是我们的高级副总裁和首席财务官。在加入Momenta之前,Storer先生是Baxalta,Inc.(一家制药公司)的财务高级副总裁,该公司于2015年7月从Baxter International分拆出来,他在该公司为Baxalta的全球商业,制造,研究与开发和职能团队提供财务领导,内部控制和业务伙伴关系支持。此外,他曾领导Baxalta公司的企业财务规划和分析团队。在此之前,Storer从2008年到2015年7月担任Baxter Bioscience Finance Vice President,为Bioscience US Commercial Organization、全球制造、研究与开发、业务发展和所有支持职能部门提供财务领导、内部控制和业务伙伴关系支持。Storer从1997年到2008年在Baxter担任多个其他职位,包括从2006年到2008年担任Bioscience Operations Finance Vice President。Storer先生在科罗拉多大学博尔德分校(University of Colorado,Boulder)获得学士学位,在西北大学凯洛格管理学院(Kellogg School of Management)获得工商管理硕士学位。
Scott M. Storer has been our Senior Vice President and Chief Financial Officer since November 2016. Prior to joining Momenta, Mr. Storer was Senior Vice President of Finance at Baxalta, Inc., a pharmaceutical company, following its spin-out from Baxter International in July 2015 where he provided financial leadership, internal controls, and business partnership support for Baxalta's global commercial, manufacturing, research and development, and functional teams. In addition, he led Baxalta's corporate financial planning and analysis team. Before that, from 2008 to July 2015 Mr. Storer served as Vice President of BioScience Finance at Baxter, where he provided financial leadership, internal controls and business partnership support to the BioScience US commercial organization, global manufacturing, research and development, business development and all support functions. From 1997 to 2008 Mr. Storer held various other positions at Baxter, including Vice President of BioScience Operations Finance from 2006 to 2008. Mr. Storer received his B.S. from the University of Colorado, Boulder, and his M.B.A. from Northwestern University's Kellogg School of Management.
Santiago Arroyo

Santiago Arroyo,医学博士,博士,自2017年6月以来一直担任我们的高级副总裁,开发和首席医疗官。加入Momenta之前,Arroyo博士于2015年10月至2017年5月担任波士顿制药(Boston Pharmaceuticals)的首席医疗官,负责临床前和临床开发以及监管事务。在此之前,从2010年到2015年,他是辉瑞公司(一家制药公司)心血管和新陈代谢,疼痛,神经科学,再生医学和罕见病领域临床研究的高级副总裁,负责人,生物疗法和PharmaTherapeutics的首席医疗官。Arroyo从2007年到2010年担任Bristol-Myers Squibb(一家制药公司)神经科学、发现医学和临床药理学治疗区域主管,从2004年到2007年担任Eisai Global Clinical Development(一家制药公司)分部神经学全球治疗区域主管。Arroyo博士于1994年在约翰霍普金斯医院(Johns Hopkins Hospital)担任神经学讲师,并于1994年至2003年在威斯康辛医学院(Medical College of Wisconsin)担任神经学副教授和癫痫项目主任,并在西班牙巴塞罗那医院诊所(Hospital Clinic)担任高级专家。Arroyo博士在马德里自治大学(Autonomous University of Madrid)获得医学博士学位,在西班牙巴塞罗那大学(University of Barcelona)获得博士学位。


Santiago Arroyo, M.D., Ph.D. has been our Senior Vice President, Development and Chief Medical Officer since June 2017. Prior to joining Momenta, Dr. Arroyo was Chief Medical Officer of Boston Pharmaceuticals from October 2015 to May 2017 where he oversaw preclinical and clinical development and regulatory affairs. Prior to that, from 2010 to 2015 he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., a pharmaceutical company, in the areas of cardiovascular and metabolism, pain, neuroscience, regenerative medicine and rare diseases. From 2007 to 2010 Dr. Arroyo was Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb, a pharmaceutical company, and, from 2004 to 2007 Neurology Global Therapeutic Area Head for Eisai Global Clinical Development, a division of Eisai Co. Ltd., a pharmaceutical company. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital in 1994 and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and Senior Specialist at the Hospital Clinic of Barcelona, Spain from 1994 to 2003. Dr. Arroyo received his M.D. from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.
Santiago Arroyo,医学博士,博士,自2017年6月以来一直担任我们的高级副总裁,开发和首席医疗官。加入Momenta之前,Arroyo博士于2015年10月至2017年5月担任波士顿制药(Boston Pharmaceuticals)的首席医疗官,负责临床前和临床开发以及监管事务。在此之前,从2010年到2015年,他是辉瑞公司(一家制药公司)心血管和新陈代谢,疼痛,神经科学,再生医学和罕见病领域临床研究的高级副总裁,负责人,生物疗法和PharmaTherapeutics的首席医疗官。Arroyo从2007年到2010年担任Bristol-Myers Squibb(一家制药公司)神经科学、发现医学和临床药理学治疗区域主管,从2004年到2007年担任Eisai Global Clinical Development(一家制药公司)分部神经学全球治疗区域主管。Arroyo博士于1994年在约翰霍普金斯医院(Johns Hopkins Hospital)担任神经学讲师,并于1994年至2003年在威斯康辛医学院(Medical College of Wisconsin)担任神经学副教授和癫痫项目主任,并在西班牙巴塞罗那医院诊所(Hospital Clinic)担任高级专家。Arroyo博士在马德里自治大学(Autonomous University of Madrid)获得医学博士学位,在西班牙巴塞罗那大学(University of Barcelona)获得博士学位。
Santiago Arroyo, M.D., Ph.D. has been our Senior Vice President, Development and Chief Medical Officer since June 2017. Prior to joining Momenta, Dr. Arroyo was Chief Medical Officer of Boston Pharmaceuticals from October 2015 to May 2017 where he oversaw preclinical and clinical development and regulatory affairs. Prior to that, from 2010 to 2015 he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc., a pharmaceutical company, in the areas of cardiovascular and metabolism, pain, neuroscience, regenerative medicine and rare diseases. From 2007 to 2010 Dr. Arroyo was Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb, a pharmaceutical company, and, from 2004 to 2007 Neurology Global Therapeutic Area Head for Eisai Global Clinical Development, a division of Eisai Co. Ltd., a pharmaceutical company. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital in 1994 and Associate Professor of Neurology and Director of the Epilepsy Program at the Medical College of Wisconsin and Senior Specialist at the Hospital Clinic of Barcelona, Spain from 1994 to 2003. Dr. Arroyo received his M.D. from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.
Young Kwon

自2015年8月以来,Young Kwon一直是我们高级副总裁,的企业发展和战略。从2011年1月至2015年7月,权先生担任我们的Vice President,企业发展和战略。加入我们之前,他曾担任Biogen Idec公司的高级业务开发董事,在那里他曾领导公司开发活动,包括评估并购、合资企业和其他战略交易。在此之前,他在Advanced Technology Ventures识别和投资早期生命科学公司。权先生于1994年在麻省理工学院(Massachusetts Institute of Technology)获得学士学位,并于1999年在哈佛大学(Harvard University)获得生物化学和分子药理学博士学位。


Young Kwon has been our Senior Vice President, Corporate Development and Strategy since August 2015. From January 2011 to July 2015 Mr. Kwon served as our Vice President, Corporate Development and Strategy. Prior to joining us, Mr. Kwon was Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. Mr. Kwon received his B.S. from the Massachusetts Institute of Technology in 1994 and his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University in 1999.
自2015年8月以来,Young Kwon一直是我们高级副总裁,的企业发展和战略。从2011年1月至2015年7月,权先生担任我们的Vice President,企业发展和战略。加入我们之前,他曾担任Biogen Idec公司的高级业务开发董事,在那里他曾领导公司开发活动,包括评估并购、合资企业和其他战略交易。在此之前,他在Advanced Technology Ventures识别和投资早期生命科学公司。权先生于1994年在麻省理工学院(Massachusetts Institute of Technology)获得学士学位,并于1999年在哈佛大学(Harvard University)获得生物化学和分子药理学博士学位。
Young Kwon has been our Senior Vice President, Corporate Development and Strategy since August 2015. From January 2011 to July 2015 Mr. Kwon served as our Vice President, Corporate Development and Strategy. Prior to joining us, Mr. Kwon was Senior Director of Business Development at Biogen Idec, where he led corporate development activities, including evaluation of mergers and acquisitions, joint ventures and other strategic transactions. Prior to that, he identified and invested in early-stage life science companies at Advanced Technology Ventures. Mr. Kwon received his B.S. from the Massachusetts Institute of Technology in 1994 and his Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University in 1999.
Craig A. Wheeler

Craig A. Wheeler,从2007年5月开始担任董事长,目前担任审计委员会成员和公司管理委员会和行政委员会主席。他在Momenta制药公司董事兼CEO。2006年8月加入Momenta 之前,他在Chiron生物制药公司(Chiron公司的一个分公司)担任了5年总裁,直到2006年被诺华制药公司收购。他负责公司各方面事务包括商业广告、研究、发展和制造。他现在在Generic制药公司董事会任职,也是其行政委员会成员。他目前也在康乃尔生物医学工程咨询委员会和波士顿儿童医院Gene Partnership咨询委员会任职。他拥有康乃尔大学化学工程理科学士和硕士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位,专业为市场营销和金融。


Craig A. Wheeler has served as our president and a director since August 2006 and was appointed our chief executive officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as president of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler serves on the board of Amicus Therapeutics, Inc., including serving on the science and compensation committees. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co., Ltd., from September 2005 to January 2015 including serving on the corporate governance and audit committees, and serving as chairman of the board beginning May 2007. Mr. Wheeler has been a member of the board of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, for over eight years, including serving as chairman of the board from 2014 to 2016 and as a member of the executive committee for the past six years. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Craig A. Wheeler,从2007年5月开始担任董事长,目前担任审计委员会成员和公司管理委员会和行政委员会主席。他在Momenta制药公司董事兼CEO。2006年8月加入Momenta 之前,他在Chiron生物制药公司(Chiron公司的一个分公司)担任了5年总裁,直到2006年被诺华制药公司收购。他负责公司各方面事务包括商业广告、研究、发展和制造。他现在在Generic制药公司董事会任职,也是其行政委员会成员。他目前也在康乃尔生物医学工程咨询委员会和波士顿儿童医院Gene Partnership咨询委员会任职。他拥有康乃尔大学化学工程理科学士和硕士学位以及宾夕法尼亚大学沃顿商学院工商管理硕士学位,专业为市场营销和金融。
Craig A. Wheeler has served as our president and a director since August 2006 and was appointed our chief executive officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as president of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler serves on the board of Amicus Therapeutics, Inc., including serving on the science and compensation committees. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc., which was acquired by Otsuka Pharmaceuticals Co., Ltd., from September 2005 to January 2015 including serving on the corporate governance and audit committees, and serving as chairman of the board beginning May 2007. Mr. Wheeler has been a member of the board of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, for over eight years, including serving as chairman of the board from 2014 to 2016 and as a member of the executive committee for the past six years. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania.
Ganesh Venkataraman Kaundinya

Ganesh Venkataraman Kaundinya,他是我们公司的联席创始人。2007年9月开始就是我们的首席科学官。2005年4月开始是研究部的高级副总裁。2002年1月到2005年4月,是我们科技部的副总裁。他从麻省理工学院(the Massachusetts Institute of Technology)收到他的化学工程硕士和博士学位。


Ganesh Venkataraman Kaundinya, Ph.D., is a co-founder of our company, has been our Chief Scientific Officer since September 2007 and has been our Chief Operating Officer since September, 2017. Dr. Kaundinya was previously our Senior Vice President, Research from April 2005 to September 2017. From January 2002 through April 2005 he served as our Vice President, Technology. Dr. Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Ganesh Venkataraman Kaundinya,他是我们公司的联席创始人。2007年9月开始就是我们的首席科学官。2005年4月开始是研究部的高级副总裁。2002年1月到2005年4月,是我们科技部的副总裁。他从麻省理工学院(the Massachusetts Institute of Technology)收到他的化学工程硕士和博士学位。
Ganesh Venkataraman Kaundinya, Ph.D., is a co-founder of our company, has been our Chief Scientific Officer since September 2007 and has been our Chief Operating Officer since September, 2017. Dr. Kaundinya was previously our Senior Vice President, Research from April 2005 to September 2017. From January 2002 through April 2005 he served as our Vice President, Technology. Dr. Kaundinya received his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.
Bruce A. Leicher

Bruce A. Leicher ,2008年7月开始他是高级副总裁和总法律顾问。2008年7月开始时总法律顾问。2006年12月到2008年7月,他是阿尔特斯制药有限公司(Altus Pharmaceuticals Inc. 一家生物制药公司)的高级副总裁,总法律顾问和秘书,在他在一些生物制药公司担任高级法律之外后。他也在岜落山法律事务所( Hill & Barlow),黑尔和多尔律师事务所(Hale and Dorr )和巴特勒和宁律师事务所(Butler and Binion。)实践。他收到了罗切斯特大学(Georgetown University)的学士学位和乔治城大学法律中心博士学位。他是美国霍根的Honorable Thomas F的法律职员。他是哥伦比亚特区地方法院(District Court Judge)法官。


Bruce A. Leicher has been our Senior Vice President and General Counsel since July 2008 and Secretary since September 2008. Prior to joining Momenta, Mr. Leicher served in senior legal positions at several biopharmaceutical companies. Mr. Leicher also practiced with the law firms Hill & Barlow, Hale and Dorr, and Butler and Binion. Mr. Leicher currently serves as a member of the National Biomedical Research Foundation and as Chair of the Board of the Biosimilars Council, a division of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association. Mr. Leicher received his B.A. from the University of Rochester and his J.D. from Georgetown University Law Center. Mr. Leicher served as a law clerk to the Honorable Thomas F. Hogan, U.S. District Court Judge for the District of Columbia.
Bruce A. Leicher ,2008年7月开始他是高级副总裁和总法律顾问。2008年7月开始时总法律顾问。2006年12月到2008年7月,他是阿尔特斯制药有限公司(Altus Pharmaceuticals Inc. 一家生物制药公司)的高级副总裁,总法律顾问和秘书,在他在一些生物制药公司担任高级法律之外后。他也在岜落山法律事务所( Hill & Barlow),黑尔和多尔律师事务所(Hale and Dorr )和巴特勒和宁律师事务所(Butler and Binion。)实践。他收到了罗切斯特大学(Georgetown University)的学士学位和乔治城大学法律中心博士学位。他是美国霍根的Honorable Thomas F的法律职员。他是哥伦比亚特区地方法院(District Court Judge)法官。
Bruce A. Leicher has been our Senior Vice President and General Counsel since July 2008 and Secretary since September 2008. Prior to joining Momenta, Mr. Leicher served in senior legal positions at several biopharmaceutical companies. Mr. Leicher also practiced with the law firms Hill & Barlow, Hale and Dorr, and Butler and Binion. Mr. Leicher currently serves as a member of the National Biomedical Research Foundation and as Chair of the Board of the Biosimilars Council, a division of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association. Mr. Leicher received his B.A. from the University of Rochester and his J.D. from Georgetown University Law Center. Mr. Leicher served as a law clerk to the Honorable Thomas F. Hogan, U.S. District Court Judge for the District of Columbia.